1. Medtech Insight
  2. >>Policy & Regulation

CMS Updates Medicare Coverage For LVADs, Artificial Hearts

Agency to eliminate “coverage with evidence development” status

 
• By Sue Darcey

Patient selection criteria will be the key to allowing CMS coverage of left ventricular assist devices (LVADs) when there is no longer a coverage with evidence development requirement, the US agency wrote.

Left ventricular assist device attached to the left ventricle of the heart and the aorta
Illustration of the performance of a left ventricular assist device

The Centers for Medicare and Medicaid Services has proposed updating its policy for left ventricular assist devices (LVADs) and artificial hearts to allow Medicare coverage by removing waitlist requirements and the need to get permission from the US agency before performing bridge-to-transplants, or destination therapy of the devices.

Released on 12 August, the decision memo also lifts the “coverage with evidence development” requirements for LVADs and artificial...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

Execs On The Move: July 7–11, 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

EU Authorities Unite In Call For Urgent Overhaul Of Medtech Regulations

 
• By Amanda Maxwell

EU member states have issued a consensus statement on the urgent need to build momentum to tackle governance and centralization issues as part of much-needed reform of the EU medtech regulatory system.

‘Eyes – A Window Into The Heart’: Retinal AI Tool Predicts Future Risk Of Heart Attack And Stroke

 
• By Natasha Barrow

A deep-learning AI-based retinal image scanning tool can predict the risk of cardiovascular events over a 10-year period with 70% accuracy. The test is comparable to routine GP health checks, researchers from the University of Dundee have shown.